ATOPIC DERMATITIS

This study is monitoring the safety and effectiveness of CIBINQO tablets for treating atopic dermatitis (eczema) in real-world Japanese medical practice. It involves over 1,100 participants who are prescribed this medication as part of their regular treatment. The research tracks…

This study aims to learn about the long-term safety and effectiveness of the drug lebrikizumab for children and teenagers with moderate-to-severe eczema. It is an extension study for up to 116 weeks, enrolling about 310 participants aged 6 months to under 18 years who completed a…

This study is testing whether an experimental daily pill called PF-08049820 is safe and effective for adults with moderate to severe eczema (atopic dermatitis). About 200 participants will take either the study pill or a placebo (a pill with no medicine) for 12 weeks. Doctors wil…

This study tests whether adding UVB light therapy to standard skin creams works better than using creams alone for adults with moderate-to-severe eczema. 316 participants were randomly assigned to receive either the light therapy plus creams or just creams for at least 3 months. …

This study is testing whether people with well-controlled eczema can safely take their medication (dupilumab) less often. It will compare a reduced dosing schedule to the standard schedule in 256 teens and adults over one year. The goal is to see if spacing out injections can mai…

This study is testing an investigational drug called lebrikizumab in children and teenagers with moderate-to-severe eczema. Participants are randomly assigned to receive either the drug or a placebo to see if it improves their skin condition and reduces itching. The main goals ar…

This study is testing whether an oral medication called jaktinib can help control moderate to severe atopic dermatitis, a form of eczema. It will compare the drug to a placebo in 443 adults to see if it significantly improves skin symptoms and is safe. The goal is to provide a ne…

This study is testing whether an investigational drug called barzolvolimab can safely reduce severe itching and improve skin in adults with moderate to severe atopic dermatitis (eczema). About 131 participants will receive either the drug at one of two doses or a placebo via inje…

This study is testing an investigational injection called CM310 in 180 teenagers with moderate-to-severe eczema (atopic dermatitis). The main goal is to see how safe the treatment is and if it helps improve skin symptoms and reduce itching. All participants in this open-label stu…

This study is observing 50 patients with moderate to severe hand eczema who are starting treatment with methotrexate, a medication that affects the immune system. Researchers will track how well the drug controls eczema symptoms, how long patients stay on it, and what side effect…

This is an early-stage study to check the safety and how the body processes a new ointment called CU-10101 for atopic dermatitis (eczema). It will first test the ointment on healthy volunteers, then on people with mild to moderate eczema, to see if it is well-tolerated and to get…

This early-stage study is testing a new combination of two drugs, APG777 and APG990, for adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to see if the combination is safe and how the body handles it, comparing it directly to an existing approved drug c…

This study is testing whether a line of over-the-counter skincare products called Bodewell can help control eczema symptoms. Fifteen adults with moderate eczema will use the products for 12 weeks. Researchers will measure how much their skin improves and if their quality of life …

This study is testing whether adding an oral medication called upadacitinib to standard steroid creams is safe and works better for controlling moderate to severe eczema in young children in Japan. About 99 children aged 2 to 11 will take either the real pill or a placebo (sugar …

This study aims to understand how well the medication dupilumab works for children with severe eczema in real-world settings. It will follow 143 children in Spain, aged 6 months to 11 years, for two years to see how the treatment affects their skin, itch, and quality of life. The…

This study is checking the long-term safety and effectiveness of an investigational drug called rocatinlimab for people with moderate-to-severe eczema (atopic dermatitis). It involves over 2,600 adults and adolescents who previously took the drug in earlier studies. The main goal…

This study is observing how well the already-approved oral medication upadacitinib (RINVOQ) works for controlling moderate-to-severe eczema over two years in real-world medical settings. It involves about 770 adolescents and adults in Germany who are already prescribed this medic…

This study is testing an experimental injection called APG777 for people with moderate-to-severe eczema (atopic dermatitis). Researchers want to see if different doses of APG777 can safely reduce skin inflammation and itching better than a placebo. The trial will last up to 2 yea…

This study is testing if a daily pill called upadacitinib, when used with a standard steroid cream, is safe and effective for controlling moderate to severe eczema (atopic dermatitis). It involves over 1,500 teens and adults whose eczema is not well-controlled with creams alone. …

This study is testing whether a new injectable drug called lebrikizumab, used alone or with a standard steroid cream, can better control moderate-to-severe eczema. About 300 adults and adolescents whose eczema isn't well-controlled by current creams will participate for about 62 …

This study is testing a new injectable drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo via injection every other week for 16 weeks, followed by the drug for another 32 weeks. Th…

This trial is studying a drug called tralokinumab, given as an injection, to see how it behaves in the body and if it is safe and effective for children aged 6 to 12 with moderate-to-severe eczema. It will involve about 24 children and last for up to 194 weeks, including treatmen…

This study is testing whether people with moderate-to-severe eczema can successfully give themselves injections of an investigational medication called rocatinlimab at home. It involves 151 participants aged 12 and older who have not responded well to standard topical treatments.…

This study is testing whether a special skin care routine for babies with early eczema can prevent them from developing food allergies. Researchers are comparing two approaches: a proactive treatment using a barrier cream and a mild steroid versus standard reactive care. The goal…

This early study is testing a special bubble bath treatment called Thera-Clean for people with skin conditions like eczema, psoriasis, and epidermolysis bullosa. The treatment uses tiny bubbles to clean skin and wounds without chemicals, aiming to reduce itching, pain, odor, and …

This is a long-term safety study, not a treatment trial. Researchers are observing 8,000 children and teens with eczema who have already used Elidel cream. The goal is to track them for 10 years to see if using this common eczema medication is linked to any increased risk of deve…

This is an early safety study testing a new antibody drug called SM17. It involves 30 healthy Chinese adults to check for side effects and see how the body processes the drug when given as an injection under the skin or into a vein. The main goal is to gather basic safety informa…

This study is creating a large national registry to track how well approved eczema (atopic dermatitis) treatments work and how safe they are in real-world settings. It will follow 10,000 adult patients under the care of a dermatologist who are starting a new medication. The goal …

This early-stage study aims to understand how an experimental atopic dermatitis (eczema) medication called PF-08049820 affects how the body processes three common drugs: birth control pills, a sedative (midazolam), and a blood thinner (dabigatran). Researchers will enroll 16 heal…

This study aims to discover the earliest signs and biological causes of food allergies and eczema in children. Researchers will follow 2500 children from before birth until age 6, collecting samples and health information. The goal is to identify markers that predict which childr…

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.